Cytophage Technologies Ltd.
CYTO.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.26M | -3.31M | -3.41M | -5.78M | -5.84M |
| Total Depreciation and Amortization | 498.00K | 565.30K | 561.60K | 516.20K | 520.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 132.90K | 59.20K | 27.30K | 1.99M | 2.19M |
| Change in Net Operating Assets | 349.20K | 348.50K | 374.80K | -233.80K | -262.40K |
| Cash from Operations | -2.28M | -2.34M | -2.44M | -3.50M | -3.39M |
| Capital Expenditure | -80.40K | -340.30K | -909.50K | -953.50K | -909.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -160.70K | -160.70K | -160.70K | 5.66M | 4.02M |
| Cash from Investing | -241.10K | -501.00K | -1.07M | 4.71M | 3.11M |
| Total Debt Issued | 225.00K | 225.00K | 225.00K | 225.00K | 25.00K |
| Total Debt Repaid | -196.10K | -196.10K | -222.10K | -261.10K | -379.90K |
| Issuance of Common Stock | 1.55M | 1.55M | 5.00K | 2.51M | 2.76M |
| Repurchase of Common Stock | -2.50M | -2.50M | -2.50M | -2.50M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2.44M | 2.44M | 2.50M | -28.80K | -71.30K |
| Cash from Financing | 1.10M | 1.10M | 3.90K | -49.70K | 1.72M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.43M | -1.74M | -3.51M | 1.16M | 1.43M |